Navigation Links
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Date:4/25/2009

) at 24 weeks following the completion of treatment - Week 72 for ACHIEVE 1, and Week 48 for ACHIEVE 2/3.

About Albinterferon Alfa-2b (Albuferon)

Albinterferon alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for approximately 19 days. Research has shown that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the therapeutic proteins.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under an exclusive worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

Albuferon dosed once every two weeks has completed Phase 3 development. Global marketing applications are planned in fall 2009. In addition, Novartis has initiated a Phase 2b trial to evaluate Albuferon dosed once every four weeks.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. It is estimated that as many as 170 million people worldwide are infected with hepatitis C virus. This includes nearly four million people in the United States. When detectable levels of HCV persist in the blood for at least six months, a person is diagnosed with chronic hepatitis C. Hepatitis C virus can
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. First Human Study to Show Sun Chlorella A Supports Heart Health
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
8. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
9. Drug Development Program Started Based on CAP(R) Human Cell Line
10. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ill. , July 22, 2014 ... to physicians is spreading to previously rep-friendly specialties, ... global sales and marketing consulting firm ZS Associates. ... more than 200 U.S. pharmaceutical sales teams. The ... other prescribers meet with the pharmaceutical sales reps ...
(Date:7/22/2014)... July 22, 2014  According to the American Optometric ... spend on digital devices. An AOA survey reports that ... and 17 estimate they use an electronic device for ... AOA survey of parents revealed that only 40 percent ... for that same amount of time. Eye doctors are ...
(Date:7/22/2014)... JUNCTION, N.J. , July 22, 2014  Vernalis ... the achievement of proof-of-concept (POC) for CCP-08, the ... US prescription cough cold collaboration. Under this collaboration, ... including a successful human pilot comparative study against ... of achieving POC, Vernalis will make a milestone ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3
... 2010 Arlington Medical Resources (AMR), a provider ... diagnostic imaging industries, finds that, in the treatment ... use of vitamin K antagonists, as a class, ... oral formulation, overall low cost and widespread inclusion ...
... 2010 DSM Pharmaceutical Products, the custom manufacturing ... license agreement with c-LEcta GmbH for proprietary screening ... to c-LEcta,s proprietary alcohol dehydrogenases for enzyme screening ... manufacturing of pharmaceutical active ingredients and intermediates. Germany-based ...
Cached Medicine Technology:Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies 2DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement 2DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement 3
(Date:7/22/2014)... City, OK (PRWEB) July 22, 2014 ... the launch of the newest component of its existing ... area hospital within the regional SSM Health Care of ... affiliate health centers that shares its services with an ... primary care centers across several states. As a forward-thinking ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... Dr. Dental is excited to announce the redesign ... in mind, one of the main differences from the old ... navigation very easy. Dr. Dental is renowned for having exceptional ... dentist affordable, convenient and fun, and the new website mirrors ... appointment scheduling system right on the home page where a ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... hysterectomy using electric power morcellation, uterine cancers were present ... the procedure, according to a study published by ... in which the uterus is fragmented into smaller pieces, ... Despite the commercial availability of electric power morcellators for ... at the time of electric power morcellation (in this ...
Breaking Medicine News(10 mins):Health News:St. Anthony Hospital Expands Its Telemedicine Program with Telepsychiatry 2Health News:St. Anthony Hospital Expands Its Telemedicine Program with Telepsychiatry 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Dr. Dental Reveals Exciting New Website 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2
... , March 10 Smart Balance, Inc. (Nasdaq: SMBL ) announced today that Stephen Hughes , Chairman and Chief Executive Officer of Smart Balance, ... Tuesday, March 16, 2010 . , ... , , ... ...
... technological revolution, the "light fantastic" continues to impact people,s ... and performing intricate surgery. As the golden anniversary of ... 7th, Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ... exciting future of this amazing invention. C&EN ...
... may someday extend men,s lives, , WEDNESDAY, March 10 ... in treating late-stage prostate cancer, it often results in ... to such therapy. , Now, however, researchers working with ... the secondary tumors gain their resistance -- a finding ...
... ... investment banking and business development to LeveragePoint,s Board of Directors. , ... Cambridge, MA (PRWEB) March 10, ... Value Management software for marketing and sales, today announced that entrepreneurial advisor and seasoned ...
... ... ... , , , , ... ...
... , ... ... , , , ... ...
Cached Medicine News:Health News:Smart Balance to Present at Roth Growth Stock Conference 2Health News:Scientists Find Key to Hormone-Resistant Prostate Tumors 2Health News:Scientists Find Key to Hormone-Resistant Prostate Tumors 3Health News:Peyton Marshall Joins LeveragePoint Innovations Board 2Health News:Peyton Marshall Joins LeveragePoint Innovations Board 3Health News:Maryland Legislation Introduced to Prohibit Indoor Tanning for Minors 2Health News:Maryland Legislation Introduced to Prohibit Indoor Tanning for Minors 3Health News:Maryland Legislation Introduced to Prohibit Indoor Tanning for Minors 4Health News:Maryland Legislation Introduced to Prohibit Indoor Tanning for Minors 5Health News:Maryland Legislation Introduced to Prohibit Indoor Tanning for Minors 6Health News:Celebrate National Nutrition Month and St. Patrick's Day, Go Green With Pistachios - The Only Green Nut! 2Health News:Celebrate National Nutrition Month and St. Patrick's Day, Go Green With Pistachios - The Only Green Nut! 3Health News:Celebrate National Nutrition Month and St. Patrick's Day, Go Green With Pistachios - The Only Green Nut! 4Health News:Celebrate National Nutrition Month and St. Patrick's Day, Go Green With Pistachios - The Only Green Nut! 5
... Test is an in vitro diagnostic screen ... Changes in FSH levels in human urine ... stages of menopause. The InstaCheck® Menopause Predictor ... qualitative result and is intended for over- ...
... fine urine chemistry reagent strips. Since ... strips from start to finish, we ... prices compared to other major producers ... urine reagent strips are for the ...
... a wealth of benefits to healthcare professionals and ... measure a complete lipid profile and glucose, ALT, ... in 5 minutes per test cassette (6 minutes ... demo, click here ., ,The accuracy, speed ...
... delivers an unmatched combination of speed, accuracy and ... and monitoring a patient's A1C levels. To ... ., ,The CLIA-waived Cholestech GDX requires only a ... than 5 minutes. The system is a proven ...
Medicine Products: